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Abstract
Background: DCE@urLAB is a software application for analysis of dynamic contrast-enhanced magnetic resonance
imaging data (DCE-MRI). The tool incorporates a friendly graphical user interface (GUI) to interactively select and
analyze a region of interest (ROI) within the image set, taking into account the tissue concentration of the contrast
agent (CA) and its effect on pixel intensity.
Results: Pixel-wise model-based quantitative parameters are estimated by fitting DCE-MRI data to several
pharmacokinetic models using the Levenberg-Marquardt algorithm (LMA). DCE@urLAB also includes the
semi-quantitative parametric and heuristic analysis approaches commonly used in practice. This software application
has been programmed in the Interactive Data Language (IDL) and tested both with publicly available simulated data
and preclinical studies from tumor-bearing mouse brains.
Conclusions: A user-friendly solution for applying pharmacokinetic and non-quantitative analysis DCE-MRI in
preclinical studies has been implemented and tested. The proposed tool has been specially designed for easy
selection of multi-pixel ROIs. A public release of DCE@urLAB, together with the open source code and sample
datasets, is available at http://www.die.upm.es/im/archives/DCEurLAB/.
Keywords: DCE-MRI, Imaging, Levenberg-Marquardt, Fitting, Preclinical, Pharmacokinetics, Animal models,
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Background
Dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) involves the acquisition of sequential images
in rapid succession during and after the intravenous
administration of a, usually, low-molecular weight con-
trast agent (CA), which includes a paramagnetic compo-
nent such as gadolinium (Gd3+). This functional imaging
modality has proven to be useful in tumor differentia-
tion, being a sensitive marker of antiangiogenic treatment
effect [1,2].
When T1-weighted magnetic resonance (MR) sequen-
ces are used, the CA induces a signal enhancement related
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with the shortening of spin-lattice or longitudinal relax-
ation time (T1), the time course of which can be related to
physiological parameters. The most common CA used in
T1-weighted DCE-MRI, Gadolinium-diethylenetriamine
penta-acetic acid (Gd-DTPA), is able to transverse the vas-
cular endothelium (except when the blood-brain barrier
is intact) and enter the extravascular-extracellular space
(EES), but is unable to cross the cellular membrane. Thus,
in DCE-MRI the measured signal intensity changes derive
mostly from CA that extravasates to the EES [3,4]. The
dynamics of exchange between the capillary bed and the
EES can be evaluated and are usually modeled as an open
two-compartment model, dependent on the washout
rate between EES and plasma (kep), and the volume
transfer constant between plasma and EES, denoted as
Ktrans [5].
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DCE-MRI has been used to investigate permeability and
perfusion in small animal tumor models [6,7]. A key con-
sideration in rodents is that the concentration of CA in
vascular plasma evolves rapidly compared to tissue, and
is quite difficult to sample the maximum signal intensity
to effectively characterize the tissue pharmacokinetics.
Since sampling the blood (the gold standard in humans)
is very invasive in small animals, kinetic models that do
not rely on arterial input function (AIF)measurements are
desirable in preclinical DCE-MRI.
Therefore, the software application presented in this
manuscript is aimed at filing this gap and providing a pow-
erful and versatile T1-weighted DCE-MRI processing tool,
and at the same time, intuitive and easy-to-use in preclin-
ical studies. It has been implemented in Interactive Data
Language (IDL), accessible at http://www.exelisvis.com/
idl.
The DCE@urLAB application integrates pixel-wise
pharmacokinetic analysis using the following models:
Tofts [8], Hoffmann [9], Larsson [10], and a reference
region (RR) model [11]. The Tofts pharmacokinetic model
has been widely applied to characterize murine tumors
[12-14], as well as the Hoffmann pharmacokinetic model
[15,16]. The Larsson model has not been extensively
applied to small animal DCE-MRI, but is the third model
typically used in theoretical studies and reviews [5,17].
Finally, the RR model has been proposed as an alternative
when AIF cannot be precisely estimated.
Existing software
Model-based and semi-quantitative analysis of T1-
weighted DCE-MRI can be performed with general pur-
pose pharmacokinetic compartmental analysis packages,
either non-commercial, like WinSAAM [18], JPKD [19],
or commercial, like SAAM II [20]. These are complex
tools that require specific training and need to be adjusted
to the particular problem of DCE-MRI. Pixel-wise analy-
sis and ROI selection of images are also not included in
these platforms.
Among the software specifically designed for DCE-MRI
data are the packages BioMap [21], PermGUI and PCT
[22], Toppcat [23], DcemriS4 [24], and DATforDCEMRI
[25].
BioMap is built in IDL, and supports compartmen-
tal analysis over ROIs through the perfusion tool. Two
ROIs must be defined, one describing the CA tissue-
concentration and the other the concentration of the CA
in blood plasma (Cp). When Cp cannot be measured in
an ROI, either because the image does not contain a
large blood vessel, or the signal from the blood vessel is
corrupted by pulsation, movement or saturation effects,
a theoretical bi-exponential decay function can be used
as Cp. Published results with DCE-MRI using BioMap
include small animal studies [12,26,27]. Although BioMap
can generate pixel maps, it does not work with coarse
resolutions and is limited to the Tofts model, with a
bi-exponential model of Cp.
PermGUI and PCT [22] are freeware applications ori-
ented to extract the permeability coefficient of the blood
brain barrier (BBB) in human patients. The tools ana-
lyze DCE-MRI images using the Patlak model [28]. This
model is also used in the package Toppcat, which runs as
a plugin of ImageJ [29]. Toppcat is also free of charge for
educational and research purposes.
DcemriS4 [24] is a collection of shell scripts to help
automate the quantitative analysis of DCE-MRI and dif-
fusion weighted imaging (DWI), and written in the R
programming environment [30]. Kinetic parametric esti-
mation is performed with the Tofts model and non-
linear regression, Bayesian estimation or deconvolution
algorithms. AIF is parameterized with a tri-exponential
function [31] to obtain an analytical solution of the con-
volution integral and increase computational efficiency.
DATforDCEMRI [25] is an R package tool which allows
performing kinetic deconvolution analysis [32] and visu-
alizing the resulting pixel-wise parametric maps. Like
DcemriS4, this software package requires an end-user
training in R programming environment.
These software packages are primarily designed for
human studies and thus are not well suited for some
typical requirements of preclinical DCE-MRI, e.g., the dif-
ficulty in accurately measuring the AIF in small animals
makes that typical models in human studies cannot be
used and ultimately requires the use of the Hoffmann
or RR models. These models are not implemented in
available software packages. Other important functional-
ities such as the difficulty in reading the imaging format
produced by preclinical studies prevent from the use of
those packages by the preclinical research community.
Thus, in-house solutions are commonly used in DCE-MRI
small animal studies, using Matlab programming envi-
ronment [33,34], LabView [35] or IDL [36-39], but they
are mostly designed for a specific study and with limited
availability.
Implementation
In this section, the compartmental models implemented
in the DCE@urLAB analysis tool are described. Addi-
tional information and technical details can be found in
the “DCEurLAB Methods.pdf” document included in the
software package, accessible at http://www.die.upm.es/
im/archives/DCEurLAB/ and in the Additional file 1. This
section also includes a brief description of the graphical
user interface (GUI) usage.
DCE-MRI pharmacokinetic modeling
Model-based pharmacokinetic analysis of T1-weighted
DCE-MRI used in the DCE@urLAB application tool is
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open bi-compartmental, representing the blood plasma
and the EES, and assume some basic concepts in tracer
kinetics and MR [5]. As the CA does not enter the
intracellular space, this compartment is not considered
in the model. The blood plasma is associated with
the central compartment, the wash-out to the kidneys
and the intake from the injected contrast, while the
EES is the peripheral compartment. This compartmen-
tal scheme is shown in Figure 1. We should note that a
bi-compartmental model does not consider the complex
biology of the tumor. Although multi-compartment mod-
els have been proposed [40], the open bi-compartmental
model has been able to fit DCE-DRI data surprisingly
well and is therefore widely accepted by the research
community. Time-course changes in tissue CA concen-
tration are modeled as a result of first-order exchange
of the CA molecules between compartments. A modi-
fied general rate equation [41] describes the CA accu-
mulation and wash-out rate in the EES, under the
assumption that the CA is well-mixed in the blood
plasma:
dCe(t)
dt =
Ktrans
ve
(
Cp(t) − Ce(t)
)
, vpCp + veCe = Ct
(1)
where Ce is the CA concentration in EES, Ct is the total
CA concentration in the tissue, vp is the fractional volume
of blood plasma, and ve = Ktrans/kep is the fractional vol-
ume of EES. The physiological meaning of Ktrans depends
on the biological mechanism of CA exchange (i.e., blood
flow, permeability, or a mixed case). If no prior informa-
tion about the tissue is available, then is prudent to leave
the interpretation open.
Tofts model
The Tofts pharmacokinetic model [8,42] is derived from
Equation 1, excluding the contribution from vascular
plasma. Tofts originally proposed a bi-exponential model
Blood
plasma
Haematocrit
(Htc)
Extracellular-
extravascular
space (EES)
Transfer const. (Ktrans)
Rate constant (kep)
Contrast agent (CA)
Renal excretion
Figure 1 Pharmacokinetic model. Body compartments accessed by
low molecular weight CA injected intravenously (e.g., Gd-DTPA).
for Cp. In that case, the solution of Equation 1 for an
instantaneous bolus injection reduces to:
Ct(t) = DKtrans
2∑
i=0
ai
e−Ktranst/ve − e−mit
mi − Ktrans/ve ,
Cp(t) = D
2∑
i=0
aie−mit
(2)
from which Ktrans and ve can be estimated through a min-
imization algorithm. Amplitudes ai and time constant mi
are estimated from a population average and D is the
injected CA dose. The extended or modified Tofts model
[5] corresponds to the adding of the contribution of the
blood plasma fraction vpCp(t) to account for the tracer in
the vasculature. In this case, the unknown parameters are
Ktrans, ve, and vp. The discrete approximation measured,
or population averaged vascular plasma CA concentra-
tions at sampling times, can be solved with least-squares
minimization methods, e.g., using the matrix-vector for-
mulation of the discrete convolution:
Ct(t) = Cp(t) ∗
(
Ktranse−kept
)
(3)
The Tofts model produces reliable results if the tissue is
weakly vascularized, while the extended Tofts model can
also be applied to highly perfused tumors [43]. It is impor-
tant to note that the quantification of Tofts parameters
requires the estimation Cp(t) from the acquired MR sig-
nal. Thus, an additional MRI model has been included in
the DCE@urLAB application and is discussed later.
Hoffmannmodel
The Hoffmann model [9] is derived from the Brix model
[44] for fast bolus injection, and assumes that the CA
transfer from blood plasma to EES is a slow process. The
model establishes a direct relationship betweenMR signal
enhancement and CA exchange rates, without the need
for AIF estimation and MR quantification. After the bolus
injection, the model is described as:
S(t)
S0
= 1 + AHkep
(
e−kept − e−kelt
kel − kep
)
(4)
where S(t) is the MR signal course from tissue and S0 is
the MR signal before CA injection. The fitting parameters
are: kep; AH , which approximately corresponds to the size
of the EES; and kel, the renal elimination constant.
Larssonmodel
The Larsson model [10] uses a known blood plasma CA
concentration course, either measured from blood sam-
ples or estimated from the MRI data. It is assumed that
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the MR signal is linearly related to the CA concentration.
In that case, the MR signal is modeled as:
S(t) = S0 +
⎛
⎜⎜⎜⎝ S˙(t)N∑
i=0
ai
⎞
⎟⎟⎟⎠
N∑
i=0
ai
e−kept − e−mit
mi − kep (5)
where S˙(t) is the initial slope of the MR signal and S0 the
MR signal value prior to CA injection. Cp is approximated
as a sum of N exponentials with amplitudes ai and time
constantmi.
RRmodel
An alternative to a populations-based or estimated
AIF, is the RR model [11]. The approach uses a
well-characterized tissue to combine two versions of
Equation 1, one for the RR and another one for the tissue
of interest. This allows the removal of Cp in the solution
of the resulting equation [11].
Ct(t) = K
trans
Ktrans,r
(
Ct,r(t) +
(Ktrans,r
ve,r
− K
trans
ve
)
×
∫ t
0
Ct,r
(
t′
)
e−Ktrans(t−t′)/vedt′
) (6)
where Ct,r is the concentration of CA in the RR tissue and
Ktrans,r and ve,r are the quantitative parameters for the RR.
MRImodel
The Tofts and RR models require the calibration of CA
concentration frommeasuredMRI parameters. If the bulk
magnetic susceptibility (BMS) shift is negligible, the rela-
tionship between T1 and CA concentration is determined
by the Solomon-Bloembergen equation [45]:
1
T1(t)
= 1T10 + r1Ct(t) (7)
where T10 is the T1 value before CA injection and r1 is
the longitudinal relaxivity. The relationship between CA
concentration and the relative increase in signal intensity
can be derived from the Bloch equations for any imag-
ing sequence, e.g., the signal for a T1-weighted spin-echo
pulse sequence (at short echo time) with repetition time
(TR) is:
S(t) = S0
(
1 − eTR/T1(t)
)
(8)
From Equation 7 and 8, Ct is equal to:
Ct(t) = 1r1
(
1
TR ln
(
S0
S0 − S(t)
(
1 − e−TR/T10)
)
− 1T10
)
(9)
For spoiled gradient-echo pulse sequences with flip
angle α, the MR signal is equal to:
S(t) =
(
S0
(
1 − e−TR/T1(t)) sinα
1 − e−TR/T1(t)cosα
)
(10)
The signal intensity is converted to CA concentration in
tissue using the equation from [46] to calculate T1(t):
T1(t)−1 = − 1TR ln
⎛
⎝ 1 −
(
S(t)−S0
S0sinα + 1−m1−m cosα
)
1 −
(
S(t)−S0
S0sinα + 1−m1−m cosα
)
cosα
⎞
⎠ ,
m = e−TR/T10
(11)
and CA concentration in tissue is calculated from
Equation 7. Note that r1 and T10 must be known to
quantify the tissue concentration from the MR signal.
T10 may be estimated using the ratio of two spin-echo
images collected with different TR. The estimation error
can be reduced with a higher number of images with a
least-squares minimization algorithm.
Estimation of model parameters
Curve fitting routines have been implemented using inter-
nal IDL functions and the freely available MPFIT IDL
library [47]. MPFIT contains a set of non-linear regres-
sion algorithms for robust least-squares minimization,
based on the freely available MINPACK package (Univ.
of Chicago, http://www.netlib.org/minpack/) a library of
FORTRAN subroutines for solving nonlinear equation
systems.
DCE@urLAB uses the Levenberg-Marquardt algorithm
(LMA) [48] to perform the non-linear least squares
regression in each pixel of the analyzed ROI. LMA
has demonstrated robustness in the pharmacokinetic
modeling of DCE-MRI [49]. LMA is used to estimate
appropriate parameters in several models: Tofts (with
bi-exponential Cp of Equation 2 or solving the discrete
convolution Equation 3); the equivalent extended Tofts
model; Hoffmann (Equation 4); Larsson (Equation 5); and
also the RR model (Equation 6).
Pixel-based processing of dynamic MRI data can be
demanding in terms of memory and CPU, and hardware
requirements will vary depending on the size of data sets,
as well as the number of pixels selected. In any case, it
is recommended to run the program in systems with at
least 2 GB of RAM memory. In addition to pharmacoki-
netic modeling, model-free semi-quantitative analysis can
be performed, including IAUC (initial area under curve),
RCE (relative contrast enhancement) and TTM (time to
max enhancement) [50].
Ortuño et al. BMC Bioinformatics 2013, 14:316 Page 5 of 17
http://www.biomedcentral.com/1471-2105/14/316
Description and use of the GUI
The DCE@urLAB GUI is composed of a main window,
which opens when the tool is executed, and auxiliary
windows for results, input/output processes, or auxil-
iary activities. Figure 2 shows an appearance of the main
window once the DCE-MRI study is loaded in memory.
The complete and detailed functionality of the GUI is
described in the user manual included in the download-
able software package. A general overview is presented in
this section.
Input data
The software tool accepts DCE-MRI sequences and aux-
iliary inputs: T10 maps, AIF data and pre-calculated
ROIs. Interface functionality is disabled until a 4-
dimensional DCE-MRI study is open. The tool considers
the sequence set to be a 4D stack of images in X-Y-Z-
time order. Data can be imported from DICOM format,
Bruker BiospinMRI data format (http://www.bruker.com/
products/mr/mri.html), as well as from binary unformat-
ted data. If the dynamic MR sequence is loaded properly,
the interface will show a single 2D slice of the whole
4D data set in the left display tab, and a relative con-
trast enhancement (RCE) image in the right display tab
(Figure 2).
The platform is specially designed to perform ROI or
pixel-wise analysis over the selected ROI belonging to a
single slice in the Z dimension (Z-slice for short). These
ROIs can be exported in a custom format and subse-
quently imported in another work session.When required
for a specific MRI model, T10 maps can be loaded from
the menu file tab. AIF data can also be imported from
previously saved sessions or external acquisitions.
Displaying data sets
After loading a valid DCE-MRI sequence, main processing
options andmenus will become activated. The user is now
able to select ROIs, change parameters, as well as config-
ure visualization options. Nevertheless, other options will
not be activated until a valid ROI is drawn or imported.
The user can navigate through dynamic frames or Z-
slices to select an active ROI for the pharmacokinetic
analysis. The color palette of both MRI and RCE dis-
plays can be changed by selecting this option on the menu
Figure 2Main window interface. In this example, a mouse brain tumor study is displayed: GL261 glioblastoma (see also the Results section). The
main window interface is shown before the ROI has been selected. In the right side of the window, the RCE image is drawn with a “rainbow” color
palette. The DCE-MRI image is drawn with “black & white” color palette in the central part. The Upper slides allow changing the current time frame
and Z-slice. Other tabs, such as zoom options, ROI selection options, parametric selection and initial constants, are grouped in the left side of the
main window interface.
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bar (options drop down menu). The user can addition-
ally change the brightness, contrast, alpha channel, etc.
Pressing mouse buttons on the display images produces
different actions depending on the ROI selection mode.
When the ROI selection mode is not activated, the actions
allowed are:
• Pressing the right mouse button on any image will
plot the dynamic MR signal course of the pointed
pixel.
• If the left mouse button is pressed over the MRI
window, the value of the current pixel appears in the
information label located at the bottom of the MRI
window tab.
• When the left mouse button is pressed on the RCE
image, the RCE value (%) of the current pixel will be
shown in the associated information label.
Selecting and defining ROIs
If the ROI selectionmode is activated, right and left mouse
buttons are used to manually place ROIs in the selected
slice. The ROI types can be Box, Full or Free-drawing type.
The ROI definition depends on the type of ROI selected.
If a Box-type is selected, the upper left and bottom right
corners of the ROI are defined by pressing the left mouse
button over the image, or alternatively, typing their X and
Y coordinates in editable text fields. If the Full ROI type
is selected, the current Z-slice is then defined as a ROI.
In the Free-drawing ROI type, the user moves the pointer
while pressing down the left mouse button over the image
tomanually delineate the contour of the ROI. The ROI can
be deleted in every moment using the New ROI button
and starting again. Finally, the user must also choose the
resolution in the Z-slice, i.e., select the pixel size for pro-
cessing options. The finest resolution corresponds to the
intrinsic resolution of the image, but the user can also
select coarser resolutions from 2×2 to 10×10 pixels in the
Z-slice (x-y plane). This option allows a direct comparison
with other applications using low-resolution maps. The
selected ROIs are currently limited to a single Z-slice.
Input parameters
Processing input parameters should be checked before
each ROI analysis to obtain accurate results. Input param-
eters are organized in tabs (located on the lower-right
of the main window interface). Each tab groups a set
of related parameters. The MR signal tab contains MRI
data related constants (e.g., frame period, repetition time,
etc.). The AIF tab groups the parameters used in the
bi-exponential model for the CA concentration in blood
plasma proposed by Tofts. The CA tab must be completed
with information concerning the injected contrast (e.g.,
injection frame, relaxivity, injected dose, etc.). Finally, the
RR tab contains additional data used in the reference
region model. These input parameters will be used or
not depending on the pharmacokinetic study selected,
e.g., the AIF tab is only read when the Tofts model is
applied.
Pharmacokinetic processing and analysis
Pharmacokinetic models are estimated by pressing the
Analyze ROI button. Note that this option is inactive until
Figure 3 Pixel resolution. The pixel where pharmacokinetic modeling is performed can vary in resolution: From intrinsic image resolution (the
finest) to coarse resolution. In the figure, two different coarse resolutions are shown for a mouse GL261 glioblastoma.
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Figure 4Modeled and acquired DCE-MRI curves.Modeled (left) and acquired (right) DCE-MRI curves. The software tool can plot the time-course
changes in individual pixels or in the whole ROI. The curve can be compared with the analytic pharmacokinetic model (left plot), where the
acquired data are represented as dots and the fitted evolution as a continuous curve.
a valid ROI has been previously drawn or imported. Hoff-
mann, Tofts (standard and extended), Larsson and RR
models can be selected for analysis. Model-free param-
eters (i.e., semi-quantitative parameters) are included as
an independent option. Analytical or numerical solu-
tions of the convolution integral are automatically chosen
depending on the type of AIF loaded. Once the analy-
sis is finished, the user can select the parameter to be
displayed or saved in disk, by using the drop lists associ-
ated to each pharmacokinetic model. An example of the
result with Box-type ROIs and two different resolutions is
shown in Figure 3. The visualization menu located on the
Figure 5 QIBA test data corresponding to the Tofts model. Left: RCE values of 30 combinations of Ktrans and ve values of simulated QIBA test
data without added noise. Upper-right: curve-fitting with the Tofts model over two random points of the QIBA test data without noise. Lower-right:
curve-fitting of the Tofts model adding Gaussian noise of zero mean and σ = 20% of the signal baseline.
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Figure 6 QIBA test data corresponding to the extended Tofts model. Left: RCE values of 108 parameter combinations, adding Gaussian noise of
zero mean and σ = 20% of signal prior to CA injection. Right: Extended Tofts model fitting over three random ROIs where each ROI comprises a
single 10×10 pixels box with common parameters.
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left (Figure 2) can select the transparency and scale of the
parametric map.
The software tool also provides detailed information of
the estimated pharmacokinetic model at pixel level; if the
left mouse button is pressed when the pointer is loca-
ted over the ROI, the adjusted curve of the parametric
model associated to the selected pixel is plotted together
with the DCE-MRI sequence values. An example of this
plot is shown in Figure 4. The plot represents the model
curve with the estimated parameters displayed on the
right side.
Complementary results and data can be accessed from
themenu bar, e.g., in the Export/import drop-downmenu,
several options can be selected to export images shown on
the screen, ROI kinetics, or the set of parametric values
of the selected ROI. Single column, multiple column, and
matrix format are available.
Results
Validation using simulated data
Tofts and extended Tofts models have been validated with
the Quantitative Imaging Biomarkers Alliance (QIBA)
DCE-MRI synthetic data, which are publicly available
at http://dblab.duhs.duke.edu. The physiologic model is
described in [51] and was simulated using JSIM [52]. Two
sets of DCE-MRI images were used, corresponding to the
Tofts model and the extended Tofts model. Data is avail-
able in DICOM part 10 format. Simulation parameters of
the Tofts model were: Flip angle, 30°; TR, 5 ms; time inter-
val between frames, 0.5 s; T10 in tissue, 1000 ms; T10 in
blood vessels, 1440 ms; Haematocrit, 45%. A 10 minute
study was simulated, with injection of CA occurring at
60 s. The data in the test images was generated using
several combinations of Ktrans and ve. Ktrans takes values
{0.01, 0.02, 0.05, 0.1, 0.2, 0.35} min−1 and ve takes {0.01,
ve
Ktrans
σ=20% σ=10% σ=2%
σ=20% σ=10% σ=2%
Figure 7 Parametric map of Tofts model applied to QIBA test data. Ktrans and ve parametric maps calculated over the whole QIBA test data
(Tofts model), adding Gaussian noise of σ = 20% of the signal baseline. Coarser resolutions of 2×2 and 10×10 pixel size, with an equivalent
Gaussian noise of σ = 10% and 2% are also shown.
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Figure 8 Tofts model applied to QIBA test data. Standard deviations of Ktrans (upper) and ve (down) values calculated over the whole QIBA test
data (Tofts model), adding Gaussian noise of σ = 20% of the signal baseline, and compared with the theoretical values plotted as the diagonal line.
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0.05, 0.1, 0.2, 0.5}. The image frames contain 10×10 pixels
patches of each and combination. The vascular region was
located in the bottom strip of the image. An RCE image is
shown in Figure 5.
The extended Tofts model data have the following
parameters: Flip angle, 25°; TR, 5 ms; time interval
between frames, 0.5 s; T10 in tissue, 1000 ms; T10 in blood
vessels, 1440 ms; Haematocrit, 45%. A 3.5 min study is
simulated, with injection of CA occurring at 5 s. The data
were generated using combinations of Ktrans ,ve and vp;
Ktrans varies over {0, 0.01, 0.02, 0.05, 0.1, 0.2} min−1, ve
takes values {0.1, 0.2, 0.5}, while vp takes {0.001, 0.005,
0.01, 0.02, 0.05, 0.1}. Each combination of these three
parameters is contained in a 10×10 pixel patch. The vas-
cular region is the bottom 60×20 pixels strip of the image.
An RCE image of this test data is represented in Figure 6.
The kinetic variation of three different combinations of
parameters is also shown in Figure 6. It can be appreci-
ated that the discretization uncertainty in this data set is
larger than in the former data set (Figure 5), and it is due
to the lower value of equilibrium magnetization used in
the simulation.
Results with Tofts model applied to QIBA test data
Gaussian noise of zero mean and standard deviation (σ )
equal to 20% of the signal baseline was added to the
test data set. Box-type ROI covering the whole tissue
region was selected (i.e., 50×60 pixels with 30 combina-
tions Ktrans and ve values). Coarser resolutions were also
studied (i.e., 2×2 and 10×10 pixel size), with an equiv-
alent Gaussian noise of σ = 10% and 2% of the signal
baseline, respectively. Noise level of σ = 20% is appre-
ciated in lower-right images in Figure 5, compared with
noise free dynamic values of the same two pixels, shown
in the upper-right graphs. The fitting of discrete convolu-
tion of Equation 3 was applied to all pixels in the selected
ROI. Graphical results for and values are represented in
Figure 7. Standard deviations referenced to the theoreti-
cal values are represented in Figure 8 for Ktrans (up) and
ve (bottom).
Results with Extended Tofts model applied to QIBA test data
Gaussian noise of zero mean and σ = 20% of the signal
baseline was added to the test data set. A Box-type ROI
of 60×180 pixels was selected to cover the 108 combina-
tions of Ktrans, ve and vp values. A coarser resolution map
of 5×5 pixel size, which reduces noise σ = 4% of the base-
line signal level, was also calculated. Color maps of the
resultant parameters are represented in Figure 9. Standard
deviations and bias referenced to the theoretical values are
represented in Figure 10 for Ktrans (up) and vp (bottom).
ve = 0.5 was used in all cases.
σ=20% σ=4% σ=20% σ=4% σ=20% σ=4%
Ktrans (min-1) ve vp
Figure 9 Parametric map of extended Tofts model applied to QIBA test data. Values of Ktrans , ve and vp maps using the extended Tofts model
supplied in the QIBA test data, adding Gaussian noise of σ = 20% of the signal baseline. Parametric maps using resolution of 5×5 pixels, resulting in
an equivalent noise of σ = 4%, are also shown.
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Figure 10 Extended Tofts model applied to QIBA test data. Standard deviations of Ktrans (upper) and vp (down) values calculated over the
whole QIBA test data of extended Tofts model, adding Gaussian noise of σ = 20% of the signal baseline. Values are compared with the theoretical
values plotted as the diagonal line.
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Example with mouse brain tumor
The platform has been tested over real acquisitions of
T1-weighted DCE-MRI small animal data. Two different
C57BL/6 mouse models have been used in this study.
First, a genetically engineeredmouse (GEM, S100-v-ErbB;
Ink4a-Arf(+/-)), female, age 40 weeks, bearing a Schwan-
noma (confirmed by histopathological studies carried out
by Dr. Martí Pumarola, Murine Pathology Unit, Centre
de Biotecnologia Animal i Teràpia Gènica, UAB). Animals
from this colony generally develop oligodendrogliomas
[53], although a small percentage of animals can develop
other tumour types [54]. The second model studied was a
mouse bearing a stereotactically-induced GL261 glioblas-
toma, described elsewhere [55,56], age 20 weeks.
A bolus of CA (Gd-DTPA –Magnevist, Bayer Schering
Pharma AG, Berlin, Germany–, 50 mM in saline,
0.2 mmol/kg, 10 s duration) was manually injected after
acquiring five pre-contrast images. A series of 41 dynamic
spin-echo images was acquired with temporal resolu-
tion of 51.2 s per frame and the following parameters:
TR/TE, 200/5 ms; field of view, 17.6×17.6 mm2; slice
thickness, 1 mm; in-plane resolution, 138×138 μm/pixel.
The studies were carried out at the joint NMR facility of
the Universitat Autònoma de Barcelona and CIBER-BBN
(Cerdanyola del Vallès, Spain), using a 7 T horizontal mag-
net (BioSpec 70/30; Bruker BioSpin, Ettlingen, Germany).
Pixel-wise Hoffmann analyses were performed over
a manually delineated ROI in a Z-slice for both cases
(Figures 11 and 12, top). The MR signal courses are
shown in Figures 11 and 12 (bottom) with signifi-
cant differences in their biophysical parameters. For
the GEM Schwannoma case, kep estimated values were
0.54±0.05 min−1 for pixel (1) and 0.03±0.01 min−1 for
pixel (2), while pixel (3) region contains highly vascu-
larised tissue and the Hoffmann model did not apply
correctly in these cases (only a few pixels presented
acceptable fittings: an example is shown in Figure 11,
estimated kep = 2.81 ± 0.46 min−1). For the GL261
glioblastoma example (Figure 12), the kep estimated values
were 1.41±0.23 min−1 (tumour border, better perfusion)
and 0.29± 0.01 min−1 (tumour core). The mean kep value
for this tumour was 0.77±0.35 min−1, which is similar to
(3)
(1)
(2)
kep=0.54±0.05 min-1 kep=0.03±0.01 min-1 kep=2.81±0.46 min-1
Time (min) Time (min) Time (min)
MRI signal (relative to baseline level)  
(3)(2)(1)
Figure 11 Pixel-wise Hoffmann analysis over a manually delineated ROI in a mouse Schwannomma. Upper-left: RCE image over a Box-type
ROI with the locations of three pixels. Upper-right: kep map over a Free-drawing ROI type (Hoffmann model). Lower: MR signal courses and fitted
Hoffmann model in the three selected pixels.
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kep=0.29±0.01 min-1kep=1.41±0.23 min-1
Time (min) Time (min)
(1)
(1) (2)
(2)
RC
E 
(%
)
RC
E 
(%
)
MRI signal (relative to baseline level)  
Figure 12 Pixel-wise Hoffmann analysis over a manually delineated ROI in a stereotactically-inducedmouse GL261 glioblastoma.
Upper left: RCE image over a Free-drawing ROI type with the locations of two pixels. Upper right: kep map (min−1) over a Free-drawing ROI type
(Hoffmann model). Lower: MR signal courses and fitted Hoffmann model in the two selected pixels.
the mean values calculated for other GL261 cases in our
group (0.87 ± 0.59, n = 8). These values also agree with
previously described studies in the literature. For example,
it was possible to calculate kep from Ktrans and ve values
reported by authors in [46], which studied a rat glioma
model: the kep value calculated was 0.86 min−1. Regard-
ing to mouse glioma models, the same kep estimation
approach was possible from the study performed in [7]
taking into account graphs in their page 612: the estimated
kep value in this case was 0.75 min−1, for tumours with a
volume (60–80 mm3) similar to our GL261 (69±43 mm3).
In both cases, the differences observed in the MR sig-
nal time courses between well-perfused and badly per-
fused (hypoxic regions) agree with the ones described by
authors in [15,57].
Computational implementation and requirements
DCE@urLAB has been implemented in a flexible and
modular way, so that the addition of new analysis mod-
els is straightforward. The different models can also be
used as inline functions to allow flexibility of use and batch
programming of multiple studies for advanced users.
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Regarding complexity, the optimization (LMA) per-
formed in each pixel has a global algorithmic complexity
bound dependent on stopping criterion and number of
maximum iterations. The algorithmic complexity by iter-
ation is determined by the cost function (i.e., the pharma-
cokinetic model) through the calculation of its jacobian
matrix. It has been experimentally verified that the com-
puting time needed to perform a pharmacokinetic analysis
depends linearly on the number of pixels contained in the
ROI and the number of dynamic frames of DCE dataset.
This behaviour is expected since the average number of
iterations of the LMA does not substantially change for
large number of pixels. For example, in a 2.8 GHz Intel
Quad Core CPU with 8 GB RAM personal computer,
it took 20 seconds to fit a ROI of 1024 pixels and 40
dynamic frames to the Tofts model. Although unrealis-
tic, because tumor ROIs are smaller, the complete analysis
using the Tofts model of the whole DCE dynamic slice
(128 × 128 = 16384 pixels) and 40 dynamic frames,
took about 5 minutes in the personal computer formerly
described. A maximum of 1.5 GB RAM was required
in this case. Should more computer power be required
(e.g., with higher resolution images), the program could be
easily parallelized and several cores used.
DCE@urLAB is designed to run under Microsoft Win-
dows XP/Vista/7 (both 32 and 64 bits). In order to use
the application tool, IDL (version 6.4 or posterior) must
have been installed. Another possibility is to install the
IDL virtual machine (version 6.4 or posterior), which can
be downloaded freely and does not require a license.
Conclusions
Up to date there is no friendly software application for
pixel-wise and ROI analysis of DCE-MRI data that can
apply different pharmacokinetic models in a preclinical
environment. DCE@urLAB is a user-friendly software
designed to fulfill the potential needs of the preclini-
cal DCE-MRI community. It has been focused on the
analysis of T1-weighted DCE-MRI studies, and tested
and optimized according to the requirements of pre-
clinical data analysis. The proposed tool has also been
specially designed for easy selection of multi-pixel ROIs.
The platform incorporates the compartmental pharma-
cokinetic models of Tofts, Hoffmann, Larsson, and RR,
complemented with non-parametric analysis. Pixel-wise
and ROI options allow the user to choose from a vari-
ety of forms and pixel sizes (i.e., resolutions). If required
by the model, AIF and T10 maps can also be estimated
from the acquired data. DCE@urLAB reads multi-slice
DCE-MRI data from proprietary and binary raw formats.
Results can be exported as color maps superimposed
to the DCE image, or as text files that can easily be
read with other statistical software packages. Individual
pixel and ROI dynamic curves can also be visualized, for
easy expert interpretation and pharmacokinetics valida-
tion. The most relevant and used models in literature
(Tofts models) have been validated with publicly avail-
able simulated data. Preliminary experiments have been
conducted using T1-weighted DCE-MRI dynamic data
from tumor-bearing mouse brains. A public release of
DCE@urLAB, together with the open source code and
sample datasets, is available at http://www.die.upm.es/im/
archives/DCEurLAB/ and in Additional files 1 and 2.
Availability and requirements
Project name: DCE@urLAB 1.0
Project home page: http://www.die.upm.es/im/archives/
DCEurLAB/
Operating system(s):Microsoft Windows 7/Vista/XP
Programming language: IDL
Other requirements: IDL 6.4 or higher, IDL Virtual
Machine 6.4 or higher
License: BSD license
Additional files
Additional file 1: Compressed file (zip format) with executable
software, source code, and user manual. Unzip and read the file
“/help/DCEurLAB_UserGuide.pdf” for instructions and details.
Additional file 2: Compressed file (zip format) with examples to test
and validate the DCE@urLAB application.
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